AR and prostate cancer: It was reported that 1 nM BPA treatment induces cell proliferation in human prostate cancer cells LNCaP which contain an androgen receptor (AR) point mutation (AR-T877A) frequently associated in patients with advanced prostate cancers refractory to hormone therapy [29].